Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...

Silver prices plunged late in the North American session, hitting a weekly low beneath $33.00, sustaining its most ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...

Even though Silver hit a fresh five-day low of $33.10, it bounced off the latter and hovers in the mid $33-$34 range a troy ...

People in mostly middle-income survey countries say it’s ideal to start a family and own a home by 30, and retire by 60.

In parallel, we plan to initiate our OPAL study to explore earlier treatment for SMA patients under two years of age and have two critical milestones ahead for our cardiometabolic program with the ...

The S&P 500 closed positively and the Russell 2000 small-cap index closed flat, signaling a potential end to the correction.

Novartis NVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal ...

In this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...

Jonathan Majors says he unpacked childhood trauma during therapy and a domestic violence program he attended in the wake of his 2023 assault trial in New York City. The actor, 35, spoke to The ...